伴隨生物標記市場：策略性洞察與預測（2026-2035 年）

伴隨生物標記市場預計將從 2026 年的 71.8 億美元成長到 2035 年的 205.2 億美元，複合年成長率為 12.4%。

伴隨生物標記市場正經歷著顯著的變革，其驅動力包括精準腫瘤學模式轉移、監管機構對基於生物標記的療法的日益重視，以及標靶治療研發的複雜性不斷增加。這個市場演變的特點在於，人們逐漸認知到伴隨生物標記對於最佳化臨床療效和提高藥物研發效率至關重要，它們能夠提供生物學證據來確定患者合格治療條件、預測治療反應或識別抗藥性機制。包括次世代定序、液態生物檢體和人工智慧（AI）在內的先進分子技術的融合，正在推動更全面的生物標記發現和檢驗。製藥公司正從臨床開發的早期階段就開始整合伴隨生物標記策略，以改善患者分層，同時降低後期臨床試驗的不確定性。隨著多種具有治療價值的生物標記擴大共存於同一腫瘤類型中，醫療系統正在採用更廣泛的分子檢測策略。隨著對綜合基因組分析平台、人工智慧驅動的解讀工具和液態生物檢體技術的巨額投資，伴隨生物標記已成為全球醫療系統實現精準醫療的關鍵要素。

市場促進因素

• 精準腫瘤學藥物研發的拓展是伴隨生物標記市場的主要驅動力。標靶腫瘤療法越來越依賴檢驗的生物標記進行患者篩選。製藥公司正在針對基因定義的腫瘤群體開發療法，因為分子層面的分層能夠提高臨床療效並降低研究人群間的差異。因此，伴隨生物標記不再只是可有可無的診斷工具，而是藥物研發的關鍵要素。這種整合推動了對生物標記發現平台和合作開發夥伴關係的投資增加，從而支持治療和診斷的同步核准，伴隨生物標記的應用也在不斷擴展。全面基因組分析的日益普及，透過多重檢測的需求，進一步加速了市場成長。在腫瘤生物學中，影響治療選擇的多個可標靶治療的基因組突變正變得越來越重要。臨床檢查室正從順序生物標記檢測轉向全面基因組分析，因為單次檢測即可同時識別多個預測性生物標記。這種轉變在支持日益複雜的治療方案的同時，也減少了組織樣本的消耗。因此，能夠提供跨多種癌症類型的標準化分子資訊的基於次世代定序（NGS）的伴隨診斷生物標記平台的需求持續成長。監管機構對伴隨診斷聯合開發的支持增強了投資信心，並促進了更廣泛的應用。監管機構認知到，治療效果越來越依賴準確生物標記的識別。監管機構支持協調一致的審查流程，因為同步評估可以縮短藥物獲準與診斷試劑上市之間的延遲。因此，製藥公司在臨床開發早期階段就引入了診斷合作夥伴。這種法規環境增強了投資信心，同時促進了伴隨診斷生物標記開發策略的更廣泛應用。越來越多的以生物標記主導的臨床試驗設計推動了對標準化分子檢測的需求。現代腫瘤學試驗擴大根據腫瘤組織學類型和分子突變來招募患者。籃式試驗、傘式試驗和平台試驗正在擴展，以提高罕見基因組亞群受試者的招募效率。

市場限制因素

• 儘管臨床證據日益增多，但不同醫療體系的報銷政策差異仍限制了常規、全面的生物標記檢測。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。高品質腫瘤組織的匱乏和樣本製備方法的不一致降低了某些生物標記檢測的診斷準確性。檢體階段的差異會影響生物標記結果的可靠性。新型生物標記的快速湧現需要持續檢驗，這增加了診斷試劑生產商的研發成本。持續更新檢測方法的需求對永續產品開發構成挑戰。不同司法管轄區的監管複雜性也給尋求將新型生物標記解決方案商業化的生產商帶來了合規負擔。

對技術和生物標記類型的深入了解

• 技術發展趨勢的特徵是全面基因組分析和整合診斷平台的重要性日益凸顯。由於NGS能夠在單次檢測中識別多個基因中大量具有治療價值的基因組突變，因此已成為高級伴隨生物標記檢測的主流方法。隨著組織樣本的取得仍然有限，治療決策也變得日益複雜，醫療專業人員正從逐一進行單基因檢測轉向全面的基因組分析。因此，診斷試劑製造商不斷擴展NGS檢測組合，以支持與多家製藥公司進行同步合作。 PCR在檢測特定突變方面仍然發揮著重要作用，尤其是在需要快速獲得結果的情況下。 IHC繼續用於評估PD-L1和HER2等生物標記的蛋白質表現。 ISH是檢測基因擴增和重排的關鍵技術。當組織樣本有限時，液態生物檢體作為一種微創檢測方法正在廣泛應用。細分市場分析表明，基因生物標記佔據了最大的市場佔有率，因為大多數已通過核准的標靶癌症療法都依賴DNA水平的突變來進行患者篩選。在臨床開發中，人們越來越關注具有治療標靶的突變，例如 EGFR、KRAS、BRCA、RET、HER2、MET 和 NTRK。腫瘤學仍然是最大的治療領域，因為大多數伴隨診斷都支持標靶癌症治療。製藥公司正在擴展其基於生物標記的研發管線，涵蓋肺癌、乳癌、大腸癌、卵巢癌、黑色素瘤和血液系統惡性腫瘤。製藥和生物技術公司佔據了主要的終端用戶市場，臨床實驗室和醫院也在擴展其生物標記檢測能力。隨著高維分子資料集需要複雜的分析技術，人工智慧的整合變得越來越重要。人工智慧平台透過識別具有臨床應用價值的突變來輔助分子病理學家，同時降低報告結果的變異性。

競爭格局與策略展望

• 競爭格局包括成熟的診斷和生命科學公司，以及專注於精準腫瘤學、分子診斷和液態生物檢體的供應商。羅氏憑藉其全球最大的腫瘤藥物組合之一，以及透過羅氏診斷和Ventana醫療系統提供的全面伴隨診斷業務，保持著獨特的戰略地位，從而能夠並行開發治療藥物和伴隨診斷產品，並同步提交監管申報。凱傑憑藉其多元化的分子診斷產品組合脫穎而出，該產品組合支持PCR、NGS、樣本製備、生物資訊學和伴隨診斷開發，並與多家製藥公司進行廣泛合作。賽默飛世爾科技憑藉其涵蓋定序、PCR、實驗室自動化、試劑、軟體和臨床診斷的廣泛生命科學基礎設施，保持著戰略優勢。安捷倫科技則憑藉其在病理學、基因組學、實驗室儀器和伴隨診斷檢測開發方面的專業知識，發揮其獨特優勢，提供免疫組織化學、原位雜合反應、數位病理學和分子工作流程解決方案。 Illumina 仍然是 NGS 技術的全球領導者，也是精準腫瘤學領域全面基因組分析的重要策略夥伴。 Guardant Health 則憑藉其在液態生物檢體技術領域的領先地位脫穎而出，支持非侵入性基因組分析和伴隨診斷應用。兩家公司都在致力於透過 NGS 檢測、液態生物檢體檢測和人工智慧驅動的解讀工具的創新來拓展產品系列。在對整合式伴隨生物標記開發的需求驅動下，製藥公司與診斷儀器製造商之間的策略合作日益增加。近期一項重大進展是 Leica Biosystems 和 Celcarta 在全球推廣聯合伴隨診斷 (CDx) 開發模式，從而為全球生物製藥企業建立了一個靈活的端到端伴隨診斷框架。 Indica Labs 透過提供由人工智慧驅動的數位病理解決方案，擴展了其 CDx 能力，旨在加速藥物發現並支持伴隨診斷的共同開發。地理擴張仍然是關鍵的策略重點，各公司都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

• 伴隨生物標記市場預計將持續成長，這主要得益於精準腫瘤學、監管重點和技術創新三者的融合。從單基因檢測到全面基因組分析的轉變，標誌著精準醫療的根本性變革。儘管保險報銷差異、機構資源和檢驗要求等挑戰依然存在，但對技術、夥伴關係和全球能力的策略投資正為市場領導提供持續的競爭優勢。長期市場前景依然樂觀，伴隨生物標記有望發展成為精準醫療的關鍵驅動力，支持療法開發、患者篩選，並改善全球醫療保健系統的臨床療效。

本報告的主要特點

• 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業領域進行詳細的市場洞察。
• 競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策以開發新的收入來源。
• 適合各類讀者：適用於各種類型的組織，包括新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

• 產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發、競爭情報收集等。

調查範圍

• 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
• 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
• 競爭定位、策略、市場佔有率評估和貿易分析
• 細分市場和區域銷售成長及預測評估
• 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球伴隨生物標記市場：概述、市場規模與預測

• 市場定義和範圍
• 生物標記的概述和臨床意義
• 精準醫學中伴隨生物標記的演變
• 主要市場趨勢
• 市場規模表現分析
• 市場預測
• 精準醫療中的疾病負擔與未滿足的臨床需求
• 主要治療領域生物標記的盛行率分析
• 伴隨診斷和生物標記聯合開發的發展趨勢
• 從生物標記發現到臨床應用的工作流程
• 伴隨生物標記臨床應用趨勢

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新型生物標記發現技術
• 多體學整合在伴隨生物標記開發的應用
• 人工智慧和機器學習在生物標記發現和檢驗的應用
• 液態生物檢體和非侵入性伴隨生物標記
• 臨床試驗分析
• 伴隨生物標記和伴隨診斷的流程分析
• 數位病理學與次世代定序的整合
• 技術藍圖

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：全球伴隨生物標記市場：展望分析

• 分析：依生物標記類型
• 分析：透過檢測技術
• 分析：依樣本類型
• 分析：按治療領域
• 分析：按最終用戶

第9章 全球伴隨生物標記市場：細分市場分析

• 依生物標誌類型
  • 基因生物標記
  • 蛋白質體學生物標記
  • 轉錄組生物標記
  • 其他
• 透過檢測技術
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合反應（ISH）
  • 其他
• 依樣本類型
  • 組織切片檢查
  • 血
  • 尿
  • 腦脊髓液
  • 其他生物檢體
• 按治療區域
  • 腫瘤學
  • 神經病學
  • 自體免疫疾病
  • 感染疾病
  • 心血管疾病
  • 其他治療領域
• 最終用戶
  • 製藥和生物技術公司
  • 臨床實驗室
  • 醫院和專科診所
  • 其他

第10章 全球伴隨生物標記市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球伴隨生物標記市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 韓國
• 印度
• 澳洲
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd

13.1.1 公司概況

13.1.2 財務信息

13.1.3產品系列

13.1.4 近期進展

• QIAGEN NV
• 賽默飛世爾科技
• Agilent Technologies, Inc.
• 光明會
• Bio-Rad Laboratories, Inc.
• 雅培實驗室
• Guardant Health, Inc.
• 精確科學
• Myriad Genetics, Inc.

第14章 全球伴隨生物標記市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Companion Biomarkers Market is expected to grow at a CAGR of 12.4% from a market value of USD 7.18 billion in 2026 to USD 20.52 billion in 2035.

The companion biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision oncology, the increasing regulatory emphasis on biomarker-guided therapies, and the growing complexity of targeted therapeutic development. The market's evolution is characterized by the recognition that companion biomarkers provide biological evidence determining patient eligibility, predicting therapeutic response, or identifying resistance mechanisms, making them essential for optimizing clinical outcomes and drug development efficiency. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and artificial intelligence, is enabling more comprehensive biomarker discovery and validation. Pharmaceutical companies are integrating companion biomarker strategies during early clinical development, improving patient stratification while reducing late-stage clinical trial uncertainty. Healthcare systems are adopting broader molecular testing strategies because multiple actionable biomarkers increasingly coexist within individual tumor types. The market is witnessing significant investment in comprehensive genomic profiling platforms, AI-enabled interpretation tools, and liquid biopsy technologies, positioning companion biomarkers as a critical enabler of precision medicine across global healthcare systems.

Market Drivers

• The expansion of precision oncology drug development represents the primary driver for the companion biomarkers market. Targeted oncology therapies increasingly depend on validated biomarkers for patient selection. Pharmaceutical companies are developing therapies against genetically defined tumor populations because molecular stratification improves clinical efficacy while reducing variability across study populations. Companion biomarkers therefore become integral components of drug development rather than optional diagnostic tools. This integration is increasing investments in biomarker discovery platforms and co-development partnerships that support simultaneous therapeutic and diagnostic approvals, resulting in sustained growth in companion biomarker utilization. The increasing adoption of comprehensive genomic profiling is further accelerating market growth through demand for multiplex testing. Tumor biology increasingly involves multiple actionable genomic alterations that influence therapeutic selection. Clinical laboratories are replacing sequential biomarker testing with comprehensive genomic profiling because a single assay identifies numerous predictive biomarkers simultaneously. This transition reduces tissue consumption while supporting increasingly complex treatment pathways. Demand therefore continues expanding for NGS-based companion biomarker platforms capable of delivering standardized molecular information across diverse cancer types. Regulatory support for companion diagnostic co-development is strengthening investment confidence and encouraging broader adoption. Regulatory agencies recognize that therapeutic effectiveness increasingly depends on accurate biomarker identification. Agencies are supporting coordinated review processes because synchronized evaluation reduces delays between therapeutic approval and diagnostic availability. Drug sponsors consequently are integrating diagnostic partners much earlier during clinical development. This regulatory environment strengthens investment confidence while encouraging broader adoption of companion biomarker development strategies. The expansion of biomarker-driven clinical trial designs is increasing demand for standardized molecular assays. Modern oncology trials increasingly enroll patients according to molecular alterations rather than tumor histology alone. Basket, umbrella, and platform trials are expanding because they improve recruitment efficiency across rare genomic subsets.

Market Restraints

• Variable reimbursement policies continue limiting routine comprehensive biomarker testing across several healthcare systems despite increasing clinical evidence. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Limited availability of high-quality tumor tissue and inconsistent pre-analytical sample handling reduce diagnostic accuracy for some biomarker assays. Pre-analytical variability can affect the reliability of biomarker results. Rapid emergence of novel biomarkers creates continual validation requirements that increase development costs for diagnostic manufacturers. The need for ongoing assay updates creates challenges for sustained product development. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new biomarker solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated diagnostic platforms. NGS dominates advanced companion biomarker testing because a single assay identifies numerous actionable genomic alterations across multiple genes. Healthcare providers are replacing sequential single-gene assays with comprehensive genomic profiling because tissue availability remains limited while therapeutic decision-making is becoming increasingly complex. Diagnostic manufacturers therefore continue expanding NGS panels that support multiple pharmaceutical partnerships simultaneously. PCR remains important for focused mutation detection where rapid turnaround is prioritized. IHC continues supporting protein expression assessment for biomarkers including PD-L1 and HER2. ISH remains essential for gene amplification and rearrangement detection. Liquid biopsy is expanding for minimally invasive testing when tissue samples are limited. The segment analysis reveals that genomic biomarkers represent the largest segment because most approved targeted oncology therapies rely on DNA-level alterations for patient selection. Clinical development is increasingly focusing on actionable mutations including EGFR, KRAS, BRCA, RET, HER2, MET, and NTRK. Oncology remains the largest therapeutic area because the majority of companion diagnostics support targeted cancer therapies. Drug developers are expanding biomarker-directed pipelines across lung, breast, colorectal, ovarian, melanoma, and hematologic cancers. Pharmaceutical and biotechnology companies represent the leading end-user segment, with clinical laboratories and hospitals expanding biomarker testing capabilities. The integration of AI is becoming increasingly important because high-dimensional molecular datasets require advanced analytical methods. AI platforms are assisting molecular pathologists by identifying clinically actionable variants while reducing reporting variability.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology, molecular, and liquid biopsy providers. Roche remains strategically distinct because it combines one of the world's largest oncology pharmaceutical portfolios with a comprehensive companion diagnostics business through Roche Diagnostics and Ventana Medical Systems, developing therapeutics and companion diagnostics in parallel to enable synchronized regulatory submissions. QIAGEN differentiates itself through a diversified molecular diagnostics portfolio supporting PCR, NGS, sample preparation, bioinformatics, and companion diagnostic development, collaborating extensively with pharmaceutical sponsors. Thermo Fisher Scientific maintains strategic strength through its extensive life sciences infrastructure encompassing sequencing, PCR, laboratory automation, reagents, software, and clinical diagnostics. Agilent Technologies distinguishes itself through expertise in pathology, genomics, laboratory instrumentation, and companion diagnostic assay development, providing immunohistochemistry, in situ hybridization, digital pathology, and molecular workflow solutions. Illumina remains the global leader in NGS technology, making the company strategically important for comprehensive genomic profiling within precision oncology. Guardant Health differentiates itself through leadership in liquid biopsy technologies supporting non-invasive genomic profiling and companion diagnostic applications. Companies are pursuing product portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between pharmaceutical companies and diagnostic manufacturers are increasing, driven by the need for integrated companion biomarker development. Recent key developments include Leica Biosystems and CellCarta expanding their collaborative CDx development model globally, broadening a flexible end-to-end companion diagnostic framework for biopharma sponsors worldwide. Indica Labs expanded its CDx capabilities with an AI-driven digital pathology offering designed to accelerate drug development and support companion diagnostic co-development. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The companion biomarkers market is positioned for sustained growth driven by the convergence of precision oncology, regulatory emphasis, and technological innovation. The transition from single-gene testing toward comprehensive genomic profiling represents a fundamental shift in precision medicine. While challenges related to reimbursement variability, tissue availability, and validation requirements persist, strategic investments in technology, partnerships, and global capabilities are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with companion biomarkers evolving into a critical enabler of precision medicine, supporting therapeutic development, patient selection, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Companion Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Biomarker Overview and Clinical Significance
• 3.3 Evolution of Companion Biomarkers in Precision Medicine
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden and Unmet Clinical Needs in Precision Medicine
• 3.8 Biomarker Prevalence Analysis Across Major Therapeutic Areas
• 3.9 Companion Diagnostic-Biomarker Co-development Landscape
• 3.10 Biomarker Discovery to Clinical Implementation Workflow
• 3.11 Clinical Adoption Trends of Companion Biomarkers

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Discovery Technologies
• 6.2 Multi-Omics Integration in Companion Biomarker Development
• 6.3 AI and Machine Learning in Biomarker Discovery and Validation
• 6.4 Liquid Biopsy and Non-Invasive Companion Biomarkers
• 6.5 Clinical Trial Analysis
• 6.6 Pipeline Analysis for Companion Biomarkers and Companion Diagnostics
• 6.7 Digital Pathology and Next-Generation Sequencing Integration
• 6.8 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Companion Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Detection Technology
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Therapeutic Area
• 8.5 Analysis by End User

9. Global Companion Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Genomic Biomarkers
  • 9.1.2 Proteomic Biomarkers
  • 9.1.3 Transcriptomic Biomarkers
  • 9.1.4 Others
• 9.2 By Detection Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Polymerase Chain Reaction (PCR)
  • 9.2.3 Immunohistochemistry (IHC)
  • 9.2.4 In Situ Hybridization (ISH)
  • 9.2.5 Others
• 9.3 By Sample Type
  • 9.3.1 Tissue Biopsy
  • 9.3.2 Blood
  • 9.3.3 Urine
  • 9.3.4 Cerebrospinal Fluid
  • 9.3.5 Other Biological Samples
• 9.4 By Therapeutic Area
  • 9.4.1 Oncology
  • 9.4.2 Neurology
  • 9.4.3 Autoimmune Diseases
  • 9.4.4 Infectious Diseases
  • 9.4.5 Cardiovascular Diseases
  • 9.4.6 Other Therapeutic Areas
• 9.5 By End User
  • 9.5.1 Pharmaceutical & Biotechnology Companies
  • 9.5.2 Clinical Laboratories
  • 9.5.3 Hospitals & Specialty Clinics
  • 9.5.4 Others

10. Global Companion Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Companion Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 QIAGEN N.V.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Agilent Technologies, Inc.
• 13.5 Illumina, Inc.
• 13.6 Bio-Rad Laboratories, Inc.
• 13.7 Abbott Laboratories
• 13.8 Guardant Health, Inc.
• 13.9 Exact Sciences Corporation
• 13.10 Myriad Genetics, Inc

14. Global Companion Biomarkers Market Commercial Forecast Analysis

• 14.1 Commercial Forecast by Biomarker Technology
• 14.2 Commercial Forecast by Therapeutic Area
• 14.3 Commercial Forecast by Companion Diagnostic Platform
• 14.4 Commercial Forecast by End User
• 14.5 Commercial Forecast by Region

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends